Valuation : Relmada Therapeutics, Inc.

Market Cap 48Cr 41Cr 39Cr 35Cr 66Cr 4.52TCr 66Cr 456.36Cr 177.63Cr 2.3TCr 178.62Cr 174.75Cr 7.62TCr P/E 2026 *
-7.31x
P/E 2027 * -5.81x
Enterprise Value 48Cr 41Cr 39Cr 35Cr 66Cr 4.52TCr 66Cr 456.36Cr 177.63Cr 2.3TCr 178.62Cr 174.75Cr 7.62TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.15%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 27/10/2020
Chief Executive Officer 65 01/04/2012
Director of Finance/CFO 61 09/01/2020
Director TitleAgeSince
Director/Board Member 65 01/04/2012
Chairman 79 15/06/2017
Director/Board Member 68 12/11/2015
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+8.91% - - 48Cr
+1.03%-3.11%+39.80%+94.60% 6.82TCr
+2.01%+0.65%+49.08%+90.23% 6.42TCr
+2.01%-1.01%-15.26%+366.93% 2.65TCr
+0.74%-8.24%+2.65%-15.34% 2.56TCr
+1.30%+0.74%+31.66%-18.33% 1.99TCr
-0.38%-12.42%+224.86%+373.18% 1.71TCr
+0.65%-5.83%+1.44%+544.44% 1.49TCr
+0.42%+1.17%+52.65%+154.85% 1.41TCr
+0.56%-0.14%+23.39%+191.67% 1.24TCr
Average -5.10%-3.75%+45.59%+198.03% 2.92TCr
Weighted average by Cap. +1.06%-3.01%+42.07%+153.26%

Financials

2026 *2027 *
Net sales - -
Net income -6.49Cr -5.59Cr -5.26Cr -4.79Cr -9.02Cr -615.55Cr -9.06Cr -62Cr -24Cr -313.12Cr -24Cr -24Cr -1.04TCr -9.08Cr -7.83Cr -7.37Cr -6.71Cr -13Cr -861.51Cr -13Cr -87Cr -34Cr -438.23Cr -34Cr -33Cr -1.45TCr
Net Debt - -
Logo Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.460USD
Average target price
12.40USD
Spread / Average Target
+178.03%

Quarterly revenue - Rate of surprise